Repros Theraup (NASDAQ:RPRX)

CAPS Rating: 1 out of 5

A biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

Recs

1
Player Avatar zzlangerhans (99.77) Submitted: 10/7/2011 6:44:28 PM : Outperform Start Price: $3.84 RPRX Score: +123.77

I'm looking for a short-term rebound in Repros as the company approaches completion of their ZP-204 study. also known as the Proellex Reanimation Study. Repros has signalled that they will conclude that Proellex can be advanced back into phase III trials for endometriosis once the FDA has signed off on the trial design, and I believe that that announcement will provide upward momentum from the current eroded share price. Meanwhile, topline data from three simultaneous phase II trials of Androxal is expected by the end of 2011 and I believe that the company will announce that the data supports an application to the FDA for an SPA for a phase III trial.

Featured Broker Partners


Advertisement